• Login
    View Item 
    •   DSpace Home
    • INVESTIGACIÓN
    • Artículos WOS
    • View Item
    •   DSpace Home
    • INVESTIGACIÓN
    • Artículos WOS
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    El Repositorio Institucional de la Universidad Mayor, tiene como objetivo publicar, en formato digital, todos los objetos derivados de su producción científica, académica, cultural y artística. En palabras simples es una vitrina que pone en valor su patrimonio documental.


    InformaciónInicioAcerca deFormulariosManuales

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    xmlui.EPerson.Navigation.loginxmlui.EPerson.Navigation.register

    Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad

    Thumbnail
    Date
    2008
    Author

    Montero, Julio C [Argentina.Universidad Nacl Buenos Aires]

    Saavedra-Gajardo, Víctor [Chile. Universidad Mayor]

    Cerda-Flores, Ricardo [México. Instituto Mexicano del Seguro Social]

    Geographic location

    Note
    Tools
    Cite
    Vea como citar este artículo

    Show full item record
    Abstract
    Current strategies to treat type 2 diabetes (DMT2) include reducing insulin resistance using glitazones, supplementing with exogenous insulin, increasing endogenous insulin production with sulfonylureas and meglitinides, reducing hepatic glucose production through biguanides, and limiting postprandial glucose absorption with alpha-glucosidase inhibitors. In all of these areas, new generations of molecules with improved efficacy and safety profiles, are being investigated. Promising biological targets are rapidly emerging such as the role of lipotoxicity as a cause of glucometabolic insulin resistance, leading to a host of new molecular drug targets such as AMP-activated protein kinase (AMPK) activators, recombinant adiponectin derivatives, and fatty acid synthase (FAS) inhibitors. Insulin action can be enhanced in muscle, liver and fat, with small-molecule activators of the insulin receptor or inhibitors of protein tyrosine phosphatase (FTP)-IB. Defective glucose-stimulated insulin secretion by pancreatic B-cells could be alleviated with recombinant glucagon-like peptide (GLP-1) or agonists to the GLP-1 receptor. This review presents a new approach for obesity and DMT2 drug discovery through pharmacogenomics. Several compounds have already been validated through genetic engineering in animal models or the preliminary use of therapeutic compounds in humans.
    URI
    https://scielo.conicyt.cl/pdf/rmc/v136n1/art14.pdf
    http://dx.doi.org/10.4067/S0034-98872008000100014
    http://repositorio.umayor.cl/xmlui/handle/sibum/2858
    Collections
    • Artículos WOS

    Si usted es autor(a) de este documento y NO desea que su publicación tenga acceso público en este repositorio, por favor complete el formulario aquí.


    Contact Us | Send Feedback
    Modificado por: Sistema de Bibliotecas Universidad Mayor - SIBUM
    DSpace software copyright © 2002-2018  DuraSpace
     

     



    Contact Us | Send Feedback
    Modificado por: Sistema de Bibliotecas Universidad Mayor - SIBUM
    DSpace software copyright © 2002-2018  DuraSpace